A genome-wide association study identifies two new risk loci for Graves' disease

• DOI: 10.1038/ng.898
• Publication Date: 2011-08-14T17:23:07Z
• Keywords: Male; Risk; 0303 health sciences; Molecular Sequence Data; Histocompatibility Antigens Class II; Receptors, Thyrotropin; Graves Disease; 3. Good health; 03 medical and health sciences; Genetic Loci; Humans; Female; Genetic Predisposition to Disease; Autoantibodies; Genome-Wide Association Study

Graves' disease is a common autoimmune disorder characterized by thyroid stimulating hormone receptor autoantibodies (TRAb) and hyperthyroidism. To investigate the genetic architecture of Graves' disease, we conducted a genome-wide association study in 1,536 individuals with Graves' disease (cases) and 1,516 controls. We further evaluated a group of associated SNPs in a second set of 3,994 cases and 3,510 controls. We confirmed four previously reported loci (in the major histocompatibility complex, TSHR, CTLA4 and FCRL3) and identified two new susceptibility loci (the RNASET2-FGFR1OP-CCR6 region at 6q27 (P(combined) = 6.85 × 10(-10) for rs9355610) and an intergenic region at 4p14 (P(combined) = 1.08 × 10(-13) for rs6832151)). These newly associated SNPs were correlated with the expression levels of RNASET2 at 6q27, of CHRNA9 and of a previously uncharacterized gene at 4p14, respectively. Moreover, we identified strong associations of TSHR and major histocompatibility complex class II variants with persistently TRAb-positive Graves' disease.